Amino Acid Substitutions in the Cytochrome P-450 Lanosterol 14α-Demethylase (CYP51A1) from Azole-Resistant Candida albicans Clinical Isolates Contribute to Resistance to Azole Antifungal Agents

ABSTRACT The cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) of yeasts is involved in an important step in the biosynthesis of ergosterol. Since CYP51A1 is the target of azole antifungal agents, this enzyme is potentially prone to alterations leading to resistance to these agents. Among them, a decrease in the affinity of CYP51A1 for these agents is possible. We showed in a group of Candida albicans isolates from AIDS patients that multidrug efflux transporters were playing an important role in the resistance ofC. albicans to azole antifungal agents, but without excluding the involvement of other factors (D. Sanglard, K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother. 39:2378–2386, 1995). We therefore analyzed in closer detail changes in the affinity of CYP51A1 for azole antifungal agents. A strategy consisting of functional expression inSaccharomyces cerevisiae of the C. albicans CYP51A1 genes of sequential clinical isolates from patients was designed. This selection, which was coupled with a test of susceptibility to the azole derivatives fluconazole, ketoconazole, and itraconazole, enabled the detection of mutations in different clonedCYP51A1 genes, whose products are potentially affected in their affinity for azole derivatives. This selection enabled the detection of five different mutations in the cloned CYP51A1genes which correlated with the occurrence of azole resistance in clinical C. albicans isolates. These mutations were as follows: replacement of the glycine at position 129 with alanine (G129A), Y132H, S405F, G464S, and R467K. While the S405F mutation was found as a single amino acid substitution in a CYP51A1 gene from an azole-resistant yeast, other mutations were found simultaneously in individual CYP51A1 genes, i.e., R467K with G464S, S405F with Y132H, G129A with G464S, and R467K with G464S and Y132H. Site-directed mutagenesis of a wild-type CYP51A1gene was performed to estimate the effect of each of these mutations on resistance to azole derivatives. Each single mutation, with the exception of G129A, had a measurable effect on the affinity of the target enzyme for specific azole derivatives. We speculate that these specific mutations could combine with the effect of multidrug efflux transporters in the clinical isolates and contribute to different patterns and stepwise increases in resistance to azole derivatives.

[1]  D. Kirsch,et al.  Nucleotide sequence of cytochrome P450 LIAI (lanosterol 14α-demethylase) from Candida albicans , 1989 .

[2]  C. F. Wilkinson,et al.  Substituted imidazoles as inhibitors of microsomal oxidation and insecticide synergists , 1974 .

[3]  T. Sutter,et al.  Primary structure of the P450 lanosterol demethylase gene from Saccharomyces cerevisiae. , 1987, DNA.

[4]  D. Kirsch,et al.  Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. , 1988, Gene.

[5]  S. Kelly,et al.  Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. , 1997, FEMS microbiology letters.

[6]  F. Odds.  Resistance of clinically important yeasts to antifungal agents. , 1996, International journal of antimicrobial agents.

[7]  D. Kirsch,et al.  Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. , 1989, Nucleic acids research.

[8]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[9]  J. Chave,et al.  Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. , 1994, AIDS.

[10]  S. Kelly,et al.  Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. , 1988, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[11]  P. Janssen,et al.  Biochemical Approaches to Selective Antifungal Activity. Focus on Azole Antifungals , 1989, Mycoses.

[12]  K. Kuchler,et al.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.

[13]  R. Cannon,et al.  Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance , 1996, Antimicrobial agents and chemotherapy.

[14]  D. Kirsch,et al.  Isolation of the gene for cytochrome P450 L1A1 (lanosterol 14α-demethylase) from Candida albicans , 1988 .

[15]  T. C. White,et al.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[16]  P. Janssen,et al.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. , 1990, Biochemical Society transactions.

[17]  P. R. Montellano,et al.  Structure of Cytochrome P450: Heme-Binding Site and Heme Reactivity , 1993 .

[18]  D. Hollomon,et al.  Molecular mechanisms of azole resistance in fungi. , 1997, FEMS microbiology letters.

[19]  S. Sen Gupta,et al.  Mechanisms and clinical impact of antifungal drug resistance. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[20]  S. Kelly,et al.  Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients , 1995, FEBS letters.

[21]  Brian C. Baldwin,et al.  The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity* , 1997, The Journal of Biological Chemistry.

[22]  S. Kelly,et al.  Altered P450 activity associated with direct selection for fungal azole resistance , 1995, FEBS letters.

[23]  F. Odds,et al.  Molecular mechanisms of drug resistance in fungi. , 1994, Trends in microbiology.

[24]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[25]  J. Goudet,et al.  Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting , 1996, Journal of clinical microbiology.

[26]  F. Odds,et al.  Characterization of an azole-resistant Candida glabrata isolate , 1992, Antimicrobial Agents and Chemotherapy.

[27]  K. Kuchler,et al.  Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance. , 1994, The Journal of biological chemistry.

[28]  T. C. White,et al.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus , 1997, Antimicrobial agents and chemotherapy.

[29]  J. Wingard,et al.  Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia , 1997, Antimicrobial agents and chemotherapy.

[30]  D. Sanglard,et al.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.

[31]  D. Sanglard,et al.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. , 1997, Microbiology.

[32]  J. Broach,et al.  Vectors for high-level, inducible expression of cloned genes in yeast. , 1983 .

[33]  D. Kelly,et al.  Mode of Action and Resistance to Azole Antifungals Associated with the Formation of 14α-Methylergosta-8,24(28)-dien-3β,6α-diol , 1995 .

[34]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[35]  S. D. Black.  Cytochrome P450 Structure and Function , 1993 .

[36]  C. F. Wilkinson,et al.  Imidazole derivatives--a new class of microsomal enzyme inhibitors. , 1972, Biochemical pharmacology.

[37]  Guy H. Grant,et al.  Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam , 1994 .

[38]  M. Pfaller,et al.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  W. Seghezzi,et al.  Identification and characterization of additional members of the cytochrome P450 multigene family CYP52 of Candida tropicalis. , 1992, DNA and cell biology.

[40]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[41]  L. Koymans,et al.  P450 inhibitors of use in medical treatment: focus on mechanisms of action. , 1995, Pharmacology & therapeutics.

[42]  R. Schiestl,et al.  Improved method for high efficiency transformation of intact yeast cells. , 1992, Nucleic acids research.